Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells invitro but have additive anti-myeloma activity invivo

Experimental Hematology

Volumn 41, Issue 12, 2013, Pages 1038-1049

  Yarde, Danielle N ^a   Nace, Rebecca A ^a   Russell, Stephen J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; BETA INTERFERON; BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; PS 431; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG ANTAGONISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; VESICULAR STOMATITIS VIRUS; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL LINE, TUMOR; CELLS, CULTURED; COMBINED MODALITY THERAPY; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; MICE; MULTIPLE MYELOMA; NF-KAPPA B; ONCOLYTIC VIROTHERAPY; PYRAZINES; REAL-TIME POLYMERASE CHAIN REACTION; VESICULAR STOMATITIS; VESICULAR STOMATITIS INDIANA VIRUS; VIRUS REPLICATION;

EID: 84888864862     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.09.005     Document Type: Article

References (50)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Kyle R.A., Rajkumar S.V. Multiple myeloma. N Engl J Med 2004, 351:1860-1873.
3. Laubach J.P., Mitsiades C.S., Mahindra A., et al. Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw 2009, 7:947-960.
4. Zhou Y., Barlogie B., Shaughnessy J.D. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia 2009, 23:1941-1956.
5. Annunziata C.M., Davis R.E., Demchenko Y., et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007, 12:115-130.
6. Keats J.J., Fonseca R., Chesi M., et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007, 12:131-144.
7. Cusack J.C., Liu R., Baldwin A.S. NF- kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF- kappa B. Drug Resist Updat 1999, 2:271-273.
8. Feinman R., Koury J., Thames M., Barlogie B., Epstein J., Siegel D.S. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 1999, 93:3044-3052.
9. Yang H.H., Ma M.H., Vescio R.A., Berenson J.R. Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J Clin Oncol 2003, 21:4239-4247.
10. Baud V., Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009, 8:33-40.
11. Chaturvedi M.M., Sung B., Yadav V.R., Kannappan R., Aggarwal B.B. NF-kappaB addiction and its role in cancer: 'one size does not fit all'. Oncogene 2011, 30:1615-1630.
12. Katze M.G., Fornek J.L., Palermo R.E., Walters K.A., Korth M.J. Innate immune modulation by RNA viruses: emerging insights from functional genomics. Nat Rev Immunol 2008, 8:644-654.
13. Rahman M.M., McFadden G. Modulation of NF-kappaB signalling by microbial pathogens. Nat Rev Microbiol 2011, 9:291-306.
14. Li Z.W., Chen H., Campbell R.A., Bonavida B., Berenson J.R. NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol 2008, 15:391-399.
15. Ma M.H., Yang H.H., Parker K., et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003, 9:1136-1144.
16. Mitsiades N., Mitsiades C.S., Poulaki V., et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002, 99:14374-14379.
17. Edwards C.M., Lwin S.T., Fowler J.A., et al. Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment invivo. Am J Hematol 2009, 84:268-272.
18. Hideshima T., Mitsiades C., Akiyama M., et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003, 101:1530-1534.
19. Moreau P., Richardson P.G., Cavo M., et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012, 120:947-959.
20. Kapoor P., Ramakrishnan V., Rajkumar S.V. Bortezomib combination therapy in multiple myeloma. Semin Hematol 2012, 49:228-242.
21. Mahindra A., Laubach J., Raje N., Munshi N., Richardson P.G., Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol 2012, 9:135-143.
22. Parato K.A., Senger D., Forsyth P.A., Bell J.C. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005, 5:965-976.
23. Russell S.J., Peng K.W., Bell J.C. Oncolytic virotherapy. Nat Biotechnol 2012, 30:658-670.
24. Barber G.N. Vesicular stomatitis virus as an oncolytic vector. Viral Immunol 2004, 17:516-527.
25. Lichty B.D., Stojdl D.F., Taylor R.A., et al. Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther 2004, 15:821-831.
26. Assenberg R., Delmas O., Morin B., et al. Genomics and structure/function studies of Rhabdoviridae proteins involved in replication and transcription. Antiviral Res 2010, 87:149-161.
27. Barber G.N. VSV-tumor selective replication and protein translation. Oncogene 2005, 24:7710-7719.
28. Johnson J.E., Nasar F., Coleman J.W., et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology 2007, 360:36-49.
29. Rodriguez L.L. Emergence and re-emergence of vesicular stomatitis in the United States. Virus Res 2002, 85:211-219.
30. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., Schreiber R.D. How cells respond to interferons. Annu Rev Biochem 1998, 67:227-264.
31. Stojdl D.F., Lichty B., Knowles S., et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000, 6:821-825.
32. Stojdl D.F., Lichty B.D., tenOever B.R., et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003, 4:263-275.
33. Naik S., Nace R., Barber G.N., Russell S.J. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-beta. Cancer Gene Ther 2012, 19:443-450.
34. Obuchi M., Fernandez M., Barber G.N. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol 2003, 77:8843-8856.
35. Saloura V., Wang L.C., Fridlender Z.G., et al. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum Gene Ther 2010, 21:51-64.
36. Willmon C.L., Saloura V., Fridlender Z.G., et al. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res 2009, 69:7713-7720.
37. Naik S., Nace R., Federspiel M.J., Barber G.N., Peng K.W., Russell S.J. Curative one-shot systemic virotherapy in murine myeloma. Leukemia 2012, 26:1870-1878.
38. Du Z., Whitt M.A., Baumann J., et al. Inhibition of type I interferon-mediated antiviral action in human glioma cells by the IKK inhibitors BMS-345541 and TPCA-1. J Interferon Cytokine Res 2012, 32:368-377.
39. Dudek S.E., Luig C., Pauli E.K., Schubert U., Ludwig S. The clinically approved proteasome inhibitor PS-341 efficiently blocks influenza A virus and vesicular stomatitis virus propagation by establishing an antiviral state. J Virol 2010, 84:9439-9451.
40. Neznanov N., Dragunsky E.M., Chumakov K.M., et al. Different effect of proteasome inhibition on vesicular stomatitis virus and poliovirus replication. PLoS One 2008, 3:e1887.
41. Goel A., Dispenzieri A., Greipp P.R., Witzig T.E., Mesa R.A., Russell S.J. PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. Exp Hematol 2005, 33:784-795.
42. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
43. Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol 2001, 28:613-619.
44. LeBlanc R., Catley L.P., Hideshima T., et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth invivo and prolongs survival in a murine model. Cancer Res 2002, 62:4996-5000.
45. Mitsiades N., Mitsiades C.S., Poulaki V., et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 2002, 99:4079-4086.
46. Burke J.R., Pattoli M.A., Gregor K.R., et al. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem 2003, 278:1450-1456.
47. Russell S.J., Peng K.W. Viruses as anticancer drugs. Trends Pharmacol Sci 2007, 28:326-333.
48. Jiang Z., Georgel P., Du X., et al. CD14 is required for MyD88-independent LPS signaling. Nat Immunol 2005, 6:565-570.
49. Madlambayan G.J., Bartee E., Kim M., et al. Acute myeloid leukemia targeting by myxoma virus invivo depends on cell binding but not permissiveness to infection invitro. Leuk Res 2012, 36:619-624.
50. Chang C.L., Hsu Y.T., Wu C.C., et al. Immune mechanism of the antitumor effects generated by bortezomib. J Immunol 2012, 189:3209-3220.